HPS Pharmacies wish to advise that Boehringer Ingelheim is experiencing a supply interruption for Metalyse® as follows:
Tenecteplase (rch) 40mg
Tenecteplase (rch) 50mg
This short-term supply interruption is expected to resolve by the end of June 2022.
During this period, Boehringer Ingelheim advises that alteplase (Actilyse®) could be considered as an alternative therapy for the thrombolytic treatment of ST-elevation myocardial infarction. The product information for Metalyse® and Actilyse® are available from the Therapeutic Goods Administration (TGA).
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Boehringer Ingelheim on 1800 226 315 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates